Navigation Links
Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information
Date:11/26/2007

Landmark Meeting Dec. 6, 2007 to Address FDA's Next Big Challenge

Is the Food and Drug Administration Effectively Communicating Risk/Safety Information on Drugs and Devices to Physicians and the Public?

WASHINGTON, Nov. 26 /PRNewswire-USNewswire/ -- In 2005, FDA banned the use of a device that repairs damaged cells and treats cancer through electromagnetic waves, known as the Pap-Ion Magnetic Inductor (PAP-IMI), because of its apparent connection to patient injuries and death. However, on November 19, 2007 The Seattle Times reported that the PAP-IMI is still in use in at least five states, and that FDA has yet to issue a public statement about the risks linked with the device.

FDA's task is indeed daunting. A panel of experts will discuss and debate the issue of risk communication at a landmark colloquium, Communicating Risk/Safety Information: How FDA Is Meeting the Challenge, sponsored by the Food and Drug Law Institute (FDLI), Dec. 6, 2007, in Washington, D.C.

This meeting is the third in a series of colloquia sponsored by FDLI. Under its new strategic direction, FDLI is committed to using the colloquium series as a neutral forum to address the legal, regulatory, policy and practical implications of technological innovations affecting the food and drug industry.

As the public becomes more concerned about whether it's safe to take --- or stop taking --- their medications, FDA is making risk communication a top priority. The agency has formed an advisory committee on communication and implementing new Congressional requirements on risk evaluation. This program seeks to clarify what that means for those who must deal with adverse events and contraindications every day.

Colloquium attendees will receive:

-- Results of a study on how FDA handled the antidepressant drug controversy;

-- Analysis of the new risk evaluation and mitigation strategy (REMS) requirements;

-- Tips on developing world-class risk/safety and communications plans;

-- Vital information on FDA's new Risk Communications Advisory Committee;

-- An inside look at FDA's overall risk communications strategy from its Director of Risk Communication, Nancy Ostrove; and

-- Excerpts from FDA's Response to the IOM's Report on Drug Safety.

The expert panel includes:

-- Nancy Ostrove, Director, Risk Communication, FDA;

-- Randall Lutter, Deputy Commissioner for Policy & Planning, FDA;

-- Stuart Pape, Managing Partner, Patton Boggs;

-- Robert Dormer, Partner, Hyman Phelps & McNamara;

-- Grace-Marie Turner, President, Galen Institute;

-- Susan Newberry, Senior Vice President, Director, D.C Healthcare Practice, Ketchum Communications; and

-- Kelly Posner, Associate Professor, Columbia University.

Registration is $295 for FDLI members, $395 for non-members. Attendance is limited, so registrants are strongly urged to sign up early.

To register, visit http://fdli.org or call +1-800-956-6923 or +1-202-371-1420.

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field.


'/>"/>
SOURCE Food & Drug Law Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
2. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
3. LifeNet Health Establishes The Skin & Wound Allograft Institute
4. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
5. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
6. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
7. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
8. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
9. Bullying Prevention Institute Designed to Empower Change in Schools
10. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
11. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: